Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Avecho Biotechnology Limited manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently contains 1 pending office action. This prosecution task is assigned to 1 distinct examiner and is situated within 1 distinct art unit, suggesting a singular focus for the company's current legal efforts in this field. Having 1 distinct art unit means the company can focus its technical arguments on the set of standards within the Biotechnology & Pharmaceuticals sector.
The busiest examiner for the portfolio is KUCHARCZK, JED A, who is responsible for 1 busiest examiner pending action. This individual handles the only active matter for Avecho Biotechnology Limited at this time. Prosecution strategy should be tailored to the specific examiner and the 1 distinct examiner's preferences, as they represent the sole channel for the company's current patent applications. Because there is only 1 pending office action, the company's progress depends entirely on the outcome of the interaction with KUCHARCZK, JED A.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KUCHARCZK, JED A | 1 | 80.2% | +16.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18249647 | ORAL CANNABINOID FORMULATION COMPRISING MEDIUM CHAIN TRIGLYCERIDES AND TOCOPHERYL PHOSPHATES | KUCHARCZK, JED A | 2d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18249647 | ORAL CANNABINOID FORMULATION COMPRISING MEDIUM CHAIN TRIGLYCERIDES AND TOCOPHERYL PHOSPHATES | KUCHARCZK, JED A | 2d overdue |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18249647 | ORAL CANNABINOID FORMULATION COMPRISING MEDIUM CHAIN TRIGLYCERIDES AND TOCOPHERYL PHOSPHATES | KUCHARCZK, JED A | 1623 | §103DP | Final Rejection | 2d overdue | Pending | Apr 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial